Table 1 Clinical and laboratory characteristics
10 episodes, no. (%) | |
|---|---|
Demographics | |
Age at onset (years) | 22.93 ± 2.48 * |
Female | 10 (100) |
SLE characteristics | |
Duration (months) | 20.8 ± 12.8* |
Fever | 8 (80) |
Rash | 8 (80) |
Photosensitive | 6 (60) |
Ulcers | 5 (50) |
Arthritis/arthralgia | 10 (100) |
Serositis | 5 (50) |
Lymphadenopathy | 5 (50) |
Vasculitis | 4 (40) |
Reynaud’s phenomena | 4 (40) |
SLEDAI | 25.8 ± 5.7* |
Associated risk factors | |
Acute hypertension | 8 (80) |
<160/100 mmHg | 5 (50) |
≥170/110 mmHg | 3 (30) |
Renal failure (cr. ≥1.5 mg/dl) b | 2 (20) |
Neurological manifestations | |
Seizures | 8 (80) |
Coma | 6 (60) |
Headache | 3 (30) |
Vomiting | 3 (30) |
Cortical blindness | 2 (20) |
Stupor | 1(10) |
Laboratory findings | |
Leucopenia | 6 (60) |
Lymphopenia | 2 (20) |
Anemia | 5 (50) |
Thrombocytopenia | 3 (30) |
Proteinuria | 8 (80) |
Hypoproteinemia | 8 (80) |
Hypocomplementemia | 8 (80) |
Anti-SSA | 7 (70) |
Anti-SSB | 2 (20) |
Anti-dsDNA | 6 (60) |
Anti-RNP/Sm | 3 (30) |
Anti- Sm | 2 (20) |
Anti-Nucleosomes | 2 (20) |
aPL | 4 (40) |
Treatmentb | |
Methylprednisolone pulses | 8 (80) |
Cyclophosphamide | 8 (80) |
Outcome | |
Complete neurological recovery | 8 (80) |
Residual neurological deficit | 1(10) |
Death | 1(10) |